Mpox Vaccine Candidate May Protect People

A clinical-stage biopharmaceutical company today announced the publication of a paper entitled "Single Dose of Recombinant Chimeric Horsepox Virus (TNX‐801) Vaccination Protects Macaques from Lethal Monkeypox Challenge" in the journal peer-review journal Viruses.

Tonix Pharmaceuticals Holding Corp. confirmed the publication demonstrates that a single dose vaccination with TNX‐801 was effective at protecting non-human primates from infection with the mpox virus.

David Evans, Ph.D., FCAHS, Professor and former Vice-Dean (Research) Faculty of Medicine and Dentistry at the University of Alberta and an investigator in the study and author of the publication, stated in a press release on February 9, 2023, "It is often forgotten that vaccines don't always produce sterilizing immunity and so it's very exciting to be able to report that a horsebox-based vaccine works so well in such a challenging infection model."

The publication describes data from animals in which eight of eight vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox (central African, Congo Basin, clade).

These data show that the immunity generated by TNX‐801 was able to protect against a lethal challenge with the mpox virus and is the first study to demonstrate the efficacy of TNX‐801 vaccination against the mpox virus challenge in a non‐human primate model.

Synthetic horsepox virus is the basis for the Company's TNX-801 vaccine in development to protect against mpox and smallpox and for the Company's Recombinant Pox Virus platform to protect against other pathogens.

Additional mpox vaccine development news is posted at PrecisionVaccinations. And MpoxToday.com publishes updated research.